2022-RA-1297-ESGO A subgroup analysis of response rate by patient characteristics in patients with endometrial cancer receiving monotherapy dostarlimab in the GARNET trial

Ana Oaknin; Bhavana Pothuri; Lucy Gilbert; Renaud Sabatier; Jubilee Brown; Sharad Ghamande; Cara Mathews; David M O’Malley; Rebecca Kristeleit; Valentina Boni; Adriano Gravina; Susana Banerjee; Rowan E Miller; Joanna Pikiel; Mansoor R Miza; Tao Duan; Yuping Dong; Eleftherios Zografos; Jennifer Veneris; Anna V Tinker; NEXT Oncology Hospital Universitario Quirónsalud *Affiliation at time of study. Current affiliation

doi:10.1136/ijgc-2022-ESGO.302

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

YouTube

Podcasts

Zoom Journal Club
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

PDF

Endometrial cancer

2022-RA-1297-ESGO A subgroup analysis of response rate by patient characteristics in patients with endometrial cancer receiving monotherapy dostarlimab in the GARNET trial

Free

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password